Usona and Compass file new drug applications for psilocybin depression treatments
DoubleBlind reports that the nonprofit Usona Institute reportedly submitted a New Drug Application to the FDA on November 2, 2026 for its synthetic psilocybin candidate for major depressive disorder (MDD), a filing first reported by Psychedelic Alpha that Usona declined to comment on.